PMCB

PharmaCyte Biotech, Inc. (PMCB) | Rumor.io

PharmaCyte Biotech

PMCB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,767

Bullish sentiment (50-day avg)56%

Price to earnings ratio14

Market capitalization4.5M

Earnings per share-2.08

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.4M

Social

What share of all stock conversation is about PMCB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 16

$PMCB owns approximately 8.4 million shares of $QCLS, worth around $9 million, and has $17.7 million in cash.
The company's market capitalization is around $4 million, with a low float and high short interest, making it vulnerable to a naked short squeeze.
$PMCB's massive naked short squeeze is expected to occur, potentially causing the stock price to increase significantly, with some predictions suggesting a price of $1 or higher.

Generated by AI

Sentiment

Of the messages about PMCB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	75% +22.41	55.42% -44.58	85.59% +0.68
Bearish	—	25% -22.41	44.58% +44.58	14.41% -0.68

Bullish· Dec 8

$PMCB has a short-term fair valuation of at least $3/share, with marketable assets and cash at $5 a share, making it a major discount opportunity.
$PMCB is expected to continue its upward trajectory alongside $QCLS, as smart money is buying both stocks together, anticipating a massive week for both.
$PMCB is primed for a parabolic move, with a spike above $1.30 expected to be the first sign of a significant increase in value, followed by a potential run-up to higher levels.

Bearish· Dec 5

$PMCB's recent price action is due to its thin microcap status with momentum swings and profit-taking, rather than being a sign of a scam.
The company's low market capitalization of $30M compared to its cash reserves of $40M may make it a less attractive investment, especially at higher prices.
$PMCB's value is closely tied to the performance of $QCLS, which is seen as a potentially worthless asset if it does not generate revenue, making it a high-risk investment.

Generated by AI

Topics

Of the messages about PMCB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	96.15%	77.78%
Controversies	—	0%	3.85%	1.41%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	5.66%
Technical Analysis	—	0%	0%	15.15%

Announcements· Aug 15

PharmaCyte Biotech, Inc. (PMCB) has reached a cooperation agreement with Iroquois Capital, which includes naming two of Iroquois' director designees to PMCB's reconstituted Board of Directors.
Iroquois Capital, which owns approximately 6.7% of PMCB's outstanding shares, invested in PMCB due to its proprietary cellulose-based live cell encapsulation technology, "Cell-in-a-Box".
PMCB's stock price is trading at a significant discount to its cash on hand, with its price almost 50% lower than the initial investment made in August 2021.

Technical Analysis· Sep 16

$PMCB is trading in a channel and waiting for a breakout.
The 50 EMA is a key level for $PMCB, with a retest of the day high expected once it moves above.
$PMCB needs to break $3.73 for a retest at $4, and has a strong support level at $3.50.

Generated by AI

Community

Of the messages about PMCB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	14.29%	87.55%	42.62%
Newcomers	—	85.71%	12.45%	57.38%

Regulars· Sep 16

$PMCB's ownership in QCLS is now worth approximately $14m, and the naked short in PMCB could lead to a low float squeeze.
$PMCB's cash position of $17.7m and 74% ownership of QCLS, with a market cap of $4m, make it a prime target for algorithms and a potential takeover candidate.
A special dividend announcement from $PMCB could lead to a massive naked short squeeze, with some estimates suggesting the stock could reach $2 per share.

Newcomers· Sep 16

Newcomers to $PMCB are focusing on the company's stake in $QCLS, which has seen a significant price increase, with some users suggesting that $PMCB should follow a similar trend.
Many newcomers are comparing the share structure of $QCLS and $PMCB, with some users noting that $PMCB has a similar structure and should experience a similar price increase.
Some newcomers are speculating about the potential for $PMCB to experience a halt-up, similar to $RETO and $DLXY, and are waiting to see if it will follow in their footsteps.

Generated by AI

Also Discussed

Investors talking about PMCB also mention

#	Name	Attention
1	Virpax Pharmaceuticals Inc.VRPX	0%0
2	Data Storage CorporationDTST	0%0
3	GeoVax Labs, Inc.GOVX	0%+0
4	Petvivo Holdings IncPETV	0%-0.01
5	Brainsway LtdBWAY	0%new
6	NanoVibronix, Inc.NAOV	0%0
7	ERYP - ERYTECH Pharma S.A.	——
8	TROOPS Inc.TROO	0%0
9	WHLM - Wilhelmina International, Inc.	——
10	Zivo Bioscience Inc.ZIVO	0%0

PharmaCyte Biotech, Inc.

Healthcare
Biotechnology

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Its core platform is Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology designed to support therapies for difficult-to-treat conditions, including inoperable pancreatic cancer and other solid tumors. The company’s work centers on applying this platform to create treatment candidates that protect and deliver living cells in a controlled way. PharmaCyte Biotech is also active in related areas such as malignant ascites, reflecting a broader focus on oncology and metabolic disease applications. Headquartered in Las Vegas, Nevada, PharmaCyte Biotech operates as a research-driven company in the health technology sector, with its current business concentrated on advancing product development and commercialization efforts in specialized cellular medicine.

Website

Location

3960 Howard Hughes Parkway

Las Vegas, NV, 89169

United States

Social

What share of all stock conversation is about PMCB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 16

$PMCB owns approximately 8.4 million shares of $QCLS, worth around $9 million, and has $17.7 million in cash.
The company's market capitalization is around $4 million, with a low float and high short interest, making it vulnerable to a naked short squeeze.
$PMCB's massive naked short squeeze is expected to occur, potentially causing the stock price to increase significantly, with some predictions suggesting a price of $1 or higher.

Generated by AI

Sentiment

Of the messages about PMCB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	75% +22.41	55.42% -44.58	85.59% +0.68
Bearish	—	25% -22.41	44.58% +44.58	14.41% -0.68

Bullish· Dec 8

$PMCB has a short-term fair valuation of at least $3/share, with marketable assets and cash at $5 a share, making it a major discount opportunity.
$PMCB is expected to continue its upward trajectory alongside $QCLS, as smart money is buying both stocks together, anticipating a massive week for both.
$PMCB is primed for a parabolic move, with a spike above $1.30 expected to be the first sign of a significant increase in value, followed by a potential run-up to higher levels.

Bearish· Dec 5

$PMCB's recent price action is due to its thin microcap status with momentum swings and profit-taking, rather than being a sign of a scam.
The company's low market capitalization of $30M compared to its cash reserves of $40M may make it a less attractive investment, especially at higher prices.
$PMCB's value is closely tied to the performance of $QCLS, which is seen as a potentially worthless asset if it does not generate revenue, making it a high-risk investment.

Generated by AI

Topics

Of the messages about PMCB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	96.15%	77.78%
Controversies	—	0%	3.85%	1.41%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	5.66%
Technical Analysis	—	0%	0%	15.15%

Announcements· Aug 15

PharmaCyte Biotech, Inc. (PMCB) has reached a cooperation agreement with Iroquois Capital, which includes naming two of Iroquois' director designees to PMCB's reconstituted Board of Directors.
Iroquois Capital, which owns approximately 6.7% of PMCB's outstanding shares, invested in PMCB due to its proprietary cellulose-based live cell encapsulation technology, "Cell-in-a-Box".
PMCB's stock price is trading at a significant discount to its cash on hand, with its price almost 50% lower than the initial investment made in August 2021.

Technical Analysis· Sep 16

$PMCB is trading in a channel and waiting for a breakout.
The 50 EMA is a key level for $PMCB, with a retest of the day high expected once it moves above.
$PMCB needs to break $3.73 for a retest at $4, and has a strong support level at $3.50.

Generated by AI

Community

Of the messages about PMCB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	14.29%	87.55%	42.62%
Newcomers	—	85.71%	12.45%	57.38%

Regulars· Sep 16

$PMCB's ownership in QCLS is now worth approximately $14m, and the naked short in PMCB could lead to a low float squeeze.
$PMCB's cash position of $17.7m and 74% ownership of QCLS, with a market cap of $4m, make it a prime target for algorithms and a potential takeover candidate.
A special dividend announcement from $PMCB could lead to a massive naked short squeeze, with some estimates suggesting the stock could reach $2 per share.

Newcomers· Sep 16

Newcomers to $PMCB are focusing on the company's stake in $QCLS, which has seen a significant price increase, with some users suggesting that $PMCB should follow a similar trend.
Many newcomers are comparing the share structure of $QCLS and $PMCB, with some users noting that $PMCB has a similar structure and should experience a similar price increase.
Some newcomers are speculating about the potential for $PMCB to experience a halt-up, similar to $RETO and $DLXY, and are waiting to see if it will follow in their footsteps.

Generated by AI

PharmaCyte Biotech

Social

Sep 16

Sentiment

Bullish· Dec 8

Bearish· Dec 5

Topics

Announcements· Aug 15

Technical Analysis· Sep 16

Community

Regulars· Sep 16

Newcomers· Sep 16

Also Discussed

PharmaCyte Biotech, Inc.

Company Information

Location

Also Discussed

Social

Sep 16

Sentiment

Bullish· Dec 8

Bearish· Dec 5

Topics

Announcements· Aug 15

Technical Analysis· Sep 16

Community

Regulars· Sep 16

Newcomers· Sep 16